Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SG301 in Antibody-Mediated Rejection After Renal Transplantation
NCT07764627Phase 2Not yet recruiting
- Sponsor
- Shangjian Bio
- Start
- Sep 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
A Phase 2 trial of SG301 in antibody mediated rejection (AMR), sponsored by Shangjian Bio. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
SG301
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT07764627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07764627.